CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Crisaboroledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03351114
NCT03351114Phase 2Completed

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Duke University·interventional·Posted Nov 22, 2017·Updated Apr 1, 2021

In Brief

A Phase 2 clinical trial evaluating Crisaborole for Morphea. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMorphea
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 22, 2017
Enrollment StartSep 1, 2018
Primary CompletionMar 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.6 years ago

Interventions

Crisaboroledrug

Apply Crisaborole 2% ointment to affected skin twice per day.